A proof-of-concept clinical trial of IDRA-008.

Trial Profile

A proof-of-concept clinical trial of IDRA-008.

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs IDRA 008 (Primary)
  • Indications Liver disorders
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 06 Nov 2017 According to an Idera Pharmaceuticals Inc. media release, this trial is expected to initiate in the first half of 2018.
    • 11 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top